RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå : ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø - ¸ð´Þ¸®Æ¼º°, ´Ü°èº°, Ä¡·á ºÐ¾ßº°, Áö¿ªº°, °æÀﺰ, ¿¹Ãø(2020-2030³â)
RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality, By Phase, By Therapeutic Areas, By Region and Competition, 2020-2030F
»óǰÄÚµå : 1703280
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 184 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,575,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 28¾ï 7,000¸¸ ´Þ·¯, 2030³â¿¡´Â 40¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ¿¹Ãø ±â°£ Áß CAGRÀº 5.73%·Î È®´ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030
½ÃÀå ±Ô¸ð : 2024³â 28¾ï 7,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 40¾ï 1,000¸¸ ´Þ·¯
CAGR : 2025-2030³â 5.73%
±Þ¼ºÀå ºÎ¹® Èñ±ÍÁúȯ
ÃÖ´ë ½ÃÀå ºÏ¹Ì

RNA Ä¡·á´Â À¯ÀüÀÚ ¹ßÇöÀ» Ç¥ÀûÀ¸·Î »ï¾Æ ´Ù¾çÇÑ Áúº´À» Ä¡·áÇÒ ¼ö Àִ ȹ±âÀûÀÎ Á¢±Ù¹ýÀ» Á¦°øÇÏ´Â ÀÇÇÐ ¿¬±¸ÀÇ ÃÖ÷´Ü ºÐ¾ßÀÔ´Ï´Ù. ¸Þ½ÅÀú RNA(mRNA), small interfering RNA(siRNA), ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå(ASO) µîÀÇ ¸®º¸ÇÙ»ê(RNA) ºÐÀÚ¸¦ Ȱ¿ëÇÏ´Â RNA ±â¹Ý Ä¡·á´Â À¯ÀüÀÚ È°¼ºÀ» Á¶ÀýÇÏ´Â Á¤¹Ð ÁÖµµÇü ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº À¯Àü¼º Áúȯ, °¨¿°¼º Áúȯ, ¾Ï, ±×¸®°í ÇöÀç È¿°úÀûÀÎ Ä¡·á¹ýÀÌ ¾ø´Â Èñ±ÍÁúȯ¿¡ ´ëÇÑ ´ëÀÀ¿¡ Å« ±â´ë¸¦ ¸ðÀ¸°í ÀÖ½À´Ï´Ù.

±âÁ¸ ÀǾàǰ°ú ´Þ¸® RNA Ä¡·á´Â À¯ÀüÀÚ ¼öÁØ¿¡¼­ ÀÛ¿ëÇϹǷΠº¸´Ù Á¤¹ÐÇÏ°í ¸ÂÃãÈ­µÈ Ä¡·á°¡ °¡´ÉÇÕ´Ï´Ù. Àü ¼¼°è¿¡¼­ ÀÓ»ó½ÃÇèÀÌ ±ÞÁõÇÏ´Â °ÍÀº RNA °úÇÐÀÇ ¹ßÀü°ú mRNA ¹é½Å°ú °°Àº RNA ±â¹Ý Á¦Ç° °³¹ßÀÇ ¼º°øÀ» ¹Ý¿µÇÏ¿© ÇコÄɾîÀÇ Àü¸ÁÀ» ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù. Çаè, Á¦¾à»ç, ¿¬±¸±â°üÀÌ Çù·ÂÇÏ¿© ÁøÇàÇÏ´Â ÀÌ·¯ÇÑ ÀÓ»ó½ÃÇèÀº ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀο¡ ¾Õ¼­ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Æò°¡ÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

RNA ±â¼ú Çõ½ÅÀÇ °¡¼Ó

ÁÖ¿ä ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦

Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ º¹À⼺

ÁÖ¿ä ½ÃÀå µ¿Çâ

¸ÂÃãÇü ÀÇ·á¿Í Á¤¹ÐÀÇ·áÀÇ ÁøÀü

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ RNA ¿ä¹ý ÀÓ»ó½ÃÇè ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå °æÀï ±¸µµ

Á¦14Àå Àü·«Àû Á¦¾È

Á¦15Àå Á¶»çȸ»ç ¼Ò°³¡¤¸éÃ¥»çÇ×

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global RNA Therapy Clinical Trials Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.01 billion by 2030, expanding at a CAGR of 5.73% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.87 Billion
Market Size 2030USD 4.01 Billion
CAGR 2025-20305.73%
Fastest Growing SegmentRare Diseases
Largest MarketNorth America

RNA therapy represents a cutting-edge domain in medical research, offering a transformative approach to treating a wide range of diseases by targeting gene expression. Leveraging ribonucleic acid (RNA) molecules such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), RNA-based therapies provide a precision-driven method to regulate gene activity. This approach holds significant promise in addressing genetic disorders, infectious diseases, cancer, and rare conditions that currently lack effective treatment options.

Unlike conventional pharmaceuticals, RNA therapies operate at the genetic level, enabling more targeted and personalized treatment solutions. The surge in clinical trials globally reflects both advancements in RNA science and the successful development of RNA-based products, such as mRNA vaccines, which have redefined the healthcare landscape. These clinical trials, conducted through collaborations between academic institutions, pharmaceutical companies, and research organizations, are pivotal in evaluating the safety and efficacy of these innovative therapies prior to regulatory approval.

Key Market Drivers

Accelerated Innovation in RNA Technology

The market's growth is largely fueled by rapid technological advancements in RNA science, reshaping the future of medicine and therapeutic development. A critical area of progress is the refinement of RNA synthesis techniques, which now enable the creation of highly specific and efficient RNA molecules customized to target particular genes or disease pathways.

For instance, in May 2022, Moderna and the nonprofit research organization IAVI announced the initiation of Phase I clinical trials for an experimental mRNA-based HIV vaccine (mRNA-1644), with initial screenings in Rwanda and South Africa.

Further innovations in RNA modification have enhanced molecular stability, reducing degradation and improving biodistribution, which extends the therapeutic effect and reduces dosing frequency-key factors in improving patient compliance. Delivery technologies have also evolved significantly, with lipid nanoparticles and polymer-based carriers protecting RNA during systemic circulation and facilitating precise cellular uptake.

Additionally, combination RNA therapies-which integrate multiple RNA modalities or pair RNA treatments with other therapeutic strategies-are under exploration, offering synergistic potential for more comprehensive disease management.

Key Market Challenges

Complexities in Delivery Mechanisms

A major challenge within the RNA therapy clinical trials market is the effective delivery of RNA molecules to specific cells or tissues. Due to their inherent fragility, RNA molecules are susceptible to enzymatic degradation and immune system activation, limiting their therapeutic utility if not adequately protected and directed.

Moreover, RNA molecules typically exhibit short biological half-lives, requiring repeated administrations to maintain therapeutic levels. Efficient delivery systems are essential to ensure therapeutic RNA reaches the intended cellular targets while minimizing systemic exposure and off-target effects.

To overcome these barriers, researchers have developed advanced delivery platforms-most notably lipid nanoparticle formulations-that encapsulate RNA, shielding it from degradation and enhancing cellular uptake. These systems can be engineered for targeted delivery, ensuring better therapeutic outcomes and minimizing toxicity.

However, challenges remain, particularly in achieving consistent delivery across varied patient profiles and disease states, making delivery optimization a key area of ongoing research and development.

Key Market Trends

Advancing Personalized and Precision Medicine

The shift toward personalized and precision medicine is a transformative trend shaping the RNA therapy clinical trials landscape. This approach leverages individual genetic and molecular profiles to tailor therapeutic interventions, significantly improving treatment outcomes and minimizing adverse effects.

In RNA therapy, personalized medicine involves designing RNA-based therapies that target patient-specific mutations or gene expressions. This enables highly focused treatment strategies, especially for rare or complex conditions.

Precision medicine goes a step further by using genetic profiling and advanced diagnostics to predict how patients will respond to specific RNA therapies. This data-driven approach enhances treatment efficacy, optimizes resource allocation in clinical trials, and supports the development of more targeted RNA-based drug candidates.

Key Market Players

IQVIA Inc.

ICON Plc

Laboratory Corporation of America Holdings

Charles River Laboratories International, Inc.

PAREXEL International Corp.

Syneos Health

Medpace Holdings, Inc.

Novotech Inc.

PPD Inc.

Veristat, LLC.

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Therapy Clinical Trials Market, By Modality:

RNA interference

Antisense therapy Messenger RNA

Oligonucleotide

Non-antisense

Non-RNAi

RNA Therapy Clinical Trials Market, By Phase:

Phase I

Phase II

Phase III

Phase IV

RNA Therapy Clinical Trials Market, By Therapeutic Area:

Rare Diseases

Anti-infective

Anticancer

Neurological

Alimentary/Metabolic

Musculoskeletal

Cardiovascular Respiratory

Sensory

Others

RNA Therapy Clinical Trials Market, By Region:

North America

Europe

Asia-Pacific

South America

Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

6. North America RNA Therapy Clinical Trials Market Outlook

7. Europe RNA Therapy Clinical Trials Market Outlook

8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook

9. South America RNA Therapy Clinical Trials Market Outlook

10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Competitive Landscape

14. Strategic Recommendations

15. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â